In patients with chronic heart failure and an ejection fraction of 35-40%, how should guideline-directed medical therapy be initiated and uptitrated?

Initiation of GDMT in Heart Failure with EF 35-40%

For patients with chronic heart failure and ejection fraction 35-40%, start all four foundational medications rapidly and simultaneously at low doses, then uptitrate systematically every 1-2 weeks to target or maximally tolerated doses.

Core Medication Classes to Initiate

Your patient with EF 35-40% qualifies for full guideline-directed medical therapy (GDMT) as they have heart failure with reduced ejection fraction (HFrEF, defined as EF <40%). The four essential medication classes that reduce mortality and must be started are 1:

1. ACE inhibitor or ARB (or preferably ARNI if tolerated)
2. Evidence-based beta-blocker (carvedilol, metoprolol succinate, or bisoprolol)
3. Mineralocorticoid receptor antagonist (MRA) (spironolactone or eplerenone)
4. SGLT2 inhibitor (dapagliflozin or empagliflozin)

Sequencing Strategy: Start Fast, Titrate Systematically

Initial Approach (Week 1-2)

Begin with ACE inhibitor/ARB and beta-blocker simultaneously 2:

• ACE Inhibitor initiation 2:

  • Review and reduce diuretics if patient is overdiuresed
  • Consider withholding diuretics for 24 hours before first dose
  • Start with LOW dose (e.g., enalapril 2.5 mg BID, lisinopril 2.5-5 mg daily)
  • Initiate in evening when supine to minimize hypotension risk
  • Check BP, renal function, and electrolytes at 1-2 weeks

• Beta-blocker initiation 2, 3:

  • Start at very low dose (e.g., carvedilol 3.125 mg BID, metoprolol succinate 12.5-25 mg daily, bisoprolol 1.25 mg daily)
  • Patient must be euvolemic and hemodynamically stable
  • Can start simultaneously with ACE inhibitor in stable patients 3

Week 2-4: Add MRA and SGLT2i

Once ACE inhibitor and beta-blocker are tolerated:

• Add MRA 2:

  • Spironolactone 12.5-25 mg daily
  • Critical: Check potassium and creatinine after 5-7 days
  • Only start if K+ <5.0 mEq/L and creatinine <2.5 mg/dL (or <221 μmol/L)
  • Avoid if GFR <30 mL/min 3

• Add SGLT2 inhibitor 1, 4:

  • Dapagliflozin 10 mg daily or empagliflozin 10 mg daily
  • Can be started early, even before full uptitration of other medications
  • Minimal titration needed; start at target dose

Uptitration Protocol

Double doses every 1-2 weeks as tolerated 2, 5:

• ACE inhibitor: Uptitrate to target doses (e.g., enalapril 10 mg BID, lisinopril 20-40 mg daily)
• Beta-blocker: Uptitrate slowly every 2-4 weeks to target (carvedilol 25 mg BID, metoprolol succinate 200 mg daily, bisoprolol 10 mg daily) 3
• MRA: Increase to spironolactone 25-50 mg daily if tolerated
• Check BP, heart rate, renal function, and electrolytes 1-2 weeks after each dose increase 2

Critical Monitoring Parameters

At each visit, check 2:

• Blood pressure (supine and standing)
• Heart rate
• Serum creatinine and potassium
• Volume status (weight, edema, orthopnea)

Acceptable changes during uptitration:

• Creatinine increase up to 30% is acceptable and does not require stopping medication 3
• Systolic BP >90 mmHg is generally safe
• Heart rate >50-55 bpm is target

Managing Common Barriers

Hypotension

• Separate timing of medications throughout the day 3
• Reduce or eliminate other vasodilators (nitrates, calcium channel blockers)
• Reduce diuretic dose if euvolemic 3
• Do not stop beta-blocker or ACE inhibitor prematurely

Hyperkalemia

• Reduce or stop potassium supplements
• Optimize diuretic therapy
• Consider potassium binders if K+ 5.5-6.0 mEq/L
• Do not combine ACE inhibitor + ARB + MRA unless in specialized clinic 3

Worsening Renal Function

• If creatinine increases >30%, hold ACE inhibitor temporarily and recheck in 1 week 2
• Avoid NSAIDs strictly 2
• Ensure adequate perfusion (not overdiuresed)

Bradycardia or AV Block

• Reduce or stop digoxin if used 3
• Consider reducing other AV-nodal blocking agents
• Pacemaker may be needed if symptomatic bradycardia persists

Diuretic Management

Loop diuretics are for symptom control only 2:

• Use lowest dose needed to maintain euvolemia
• Always combine with ACE inhibitor 2
• Adjust dose based on daily weights and symptoms
• If GFR <30 mL/min, avoid thiazides except when combined with loop diuretics 2

Key Pitfalls to Avoid

1. Therapeutic inertia: Don't delay starting all four medication classes. Recent evidence shows early initiation (within 4 weeks) significantly reduces 1-year mortality 4

2. Stopping medications after EF improvement: If EF improves to >40%, continue all GDMT 1, 6. Patients with improved EF remain at significant risk and benefit from continued therapy.

3. Accepting suboptimal doses: While even low doses provide benefit 5, systematically uptitrate toward target doses. The goal is maximally tolerated doses, not just "some dose."

4. Premature discontinuation for side effects: Most side effects can be managed with dose adjustment or timing changes rather than stopping life-saving medications 3.

5. Avoiding MRA due to potassium concerns: With proper monitoring (check K+ and creatinine 5-7 days after initiation), MRA can be safely used and provides substantial mortality benefit 2.

Timeline Summary

• Week 1-2: Start ACE inhibitor + beta-blocker at low doses
• Week 2-4: Add MRA + SGLT2i
• Weeks 4-12: Systematically uptitrate all medications every 1-2 weeks
• Month 3+: Maintain target or maximally tolerated doses with monitoring every 3-6 months 2

The evidence is clear: rapid initiation of all four medication classes within the first month, followed by systematic uptitration, provides the greatest mortality and morbidity benefit 4. Don't delay—start comprehensively and uptitrate aggressively while monitoring closely.